Table 3.
Condition | Unrecognized | Treated | Controlled |
---|---|---|---|
HTN | 1.48 (1.20–1.83)* 1.25 (1.01 –1.55)** |
1.51 (1.28–1.79)* 1.41 (1.19–1.66)** |
0.88 (0.80 – 0.97)* 0.90 (0.82 – 0.99)** 0.93 (0.84–1.03)† |
HTN Stage 2 | 2.03 (1.35–3.08)* 1.78 (1.17–2.71)** |
0.82 (0.70 – 0.97)* 0.84 (0.72 – 0.98)** 0.87(0.73–1.02)† |
|
DM | 1.32 (1.03–1.70)* 1.35 (1.05–1.74)** |
1.72 (1.40–2.12)* 1.73 (1.40–2.12)** |
0.95 (0.82–1.10)* 0.92 (0.79–1.06)** 0.95(0.817–1.11)† |
Dyslipidemia | 0.76 (0.67 – 0.87)* 0.80 (0.70–0.91)** |
1.99 (1.77–2.23)* 1.82 (1.62–2.05)** |
1.48 (1.33–1.65)* 1.35 (1.21 –1.51)** 1.37 (1.22–1.53)† |
univariate,
adjusted for age,
adjusted for age and medication compliance measured by the Mori sky scale.